Abstract. Metastatic squamous cell carcinoma of the head and neck (SCCHN) has been shown to express chemokine receptor 7 (CCR7), which can activate signaling pathways to promote invasion and survival of SCCHN cells. We hypothesized that the RhoA/Rho-associated kinase (ROCK) pathway is involved in the CCR7-induced invasion and migration of metastatic SCCHN cells. Thus, using migration, matrigel invasion and scrape wound-healing assays, we elucidated the role of RhoA in mediating CCR7-associated cellular mobility. Pull-down assays and western blotting were used to measure RhoA and its downstream expression. Immunohistochemical staining and analysis were useful in identifying the correlation between CCR7 and RhoA expression and clinicopathological factors. The results showed that inhibition of RhoA/ROCK reduced the tumor cell migration and invasiveness induced by CCL19. Activated RhoA, proline-rich tyrosine kinase-2 (Pyk2) and cofilin induced by CCL19 were elevated, and increased RhoA, Pyk2 and cofilin activity was eliminated by CCR7mAb, RhoA/ROCK and Pyk2 inhibitors, indicating involvement of the RhoA/ROCK-Pyk2-cofilin cascade. In summary, CCR7 via RhoA/ROCK-Pyk2 cofilin pathway promotes invasion and migration of metastatic SCCHN cells.
Introduction
Squamous cell carcinoma of the head and neck (SCCHN) accounts for over 90% of all head and neck cancer (1) . The 5-year survival for patients is only 30-40%, mainly due to lymphatic metastatic and local recurrence (2) . No significant increase in the long-term survival rate has been achieved during the past 30 years, despite substantial improvements in the surgical management of radiotherapy and chemotherapy for SCCHN. The mechanisms determining the directional migration and invasion of SCCHN cells into specific organs remain to be elucidated.
Chemokines induce cytoskeleton rearrangement, firm adhesion to endothelial cells, and directional migration by binding to G-protein-coupled receptors (3) . Chemokines and their respective receptors were involved in the metastasis of several types of cancer (4) (5) (6) (7) (8) . The metastatic SCCHN cells were shown to express chemokine receptor 7 (CCR7), which activated phosphoinositide-3 kinase (PI3K) Cdc42, Pyk2, mTOR and NF-κB pathways to promote 'homing' into lymph nodes and support their survival (9) (10) (11) (12) . However, when these downstream molecules were inhibited, the effect of CCR7 was not blocked completely, revealing the involvement of other downstream signaling molecules in the process.
Attention has focused on the involvement of Rho family GTPases and their downstream effectors in chemokineelicited migration (13) (14) (15) . Important Rho effectors are the serine/threonine kinase Rho-associated kinase (ROCK) (16) . ROCKs are important Rho effectors that enhance myosin light chain (MLC) and cofilin phosphorylation, thus regulating actin-myosin contraction (17) and cell motility (18) . Pyk2 is another mediator of chemokine receptors. It has been reported that the Rho/Pyk2/cofilin pathway controls chemotaxis and the migration speed of dendritic cells (14) .
In the present study we examined whether RhoA was activated by CCR7, as well as the role and the molecular mechanisms of the RhoA pathway in CCR7 regulating SCCHN metastasis. The results showed that CCL19 induced activation of the Rho/ROCK-Pyk2-cofilin pathway, whereas MLC was not involved in the process. Reagents and antibodies. The CCR7 chemokine ligand, CCL19 (MIP-3β) was purchased from R&D Systems (Minneapolis, MN, uSA). Mouse anti-CCR7 antibody was purchased from BD Biosciences (San jose, CA, uSA). C3 exoenzyme (Rho inhibitor) was purchased from Cytoskeleton Inc. (Denver, CO, uSA) and Y-27632 (ROCK inhibitor) was purchased from Sigma (Santa Clara, CA, uSA). Tyrphostin A9 (Pyk2 inhibitor) was purchased from Calbiochem (San Diego, CA, uSA). Anti-RhoA, anti-phospho-Pyk2 (Tyr402), anti-phospho-cofilin (Ser3) and anti-phospho-myosin light chain (Ser19) were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, uSA). Bio-Rad protein assay dye reagent was purchased from Bio-Rad Laboratories (Richmond, CA, uSA). Enhanced chemiluminescence was purchased from Amersham Pharmacia Biotechnology (Piscataway, Nj, uSA).
Immunohistochemical analysis. Immunohistochemical staining used conventional horseradish peroxidase immunohistochemical staining methods. Briefly, 5-µm sections of the specimens were deparaffinized and hydrated with 0.6% H 2 O 2 in methanol to inhibit endogenous peroxidase. Antigen retrieval was performed and slides were incubated with normal blocking serum for 10 min. Sections were incubated with primary antibodies (1:100 dilution): CCR7-specific monoclonal antibody, and rabbit anti-RhoA polyclonal antibody overnight at 4˚C. Immunodetection was performed using peroxidase-labeled secondary antibody (R&D Systems) and diaminobenzidine for visualization. The sections were counterstained with hematoxylin (Sigma). Negative controls included omission of the primary antibody. Cell morphology was analyzed by microscopy (Nikon Eclipse 80i; Tokyo, japan) at x100-400 magnification. According to the percentage of positive tumor cells, the cells were scored as negative (-), <10% or no staining; weak positive (+), 11-50%; positive (++), 51-75%; or strongly positive (+++), >75%.
Chemotaxis assay. Chemotaxis in response to chemokines was measured by counting cells migrating through a polycarbonate filter (8-µm pore size) in 24-well Transwell chambers in triplicate in DMEM with 0.5% (w/v) BSA (Invitrogen). Cell suspensions (2x10 5 cells/200 µl) were placed in the top chamber of the filter. Aliquots of chemokines were added to wells. After 24 h, the cells in each lower well were counted under a light microscope in at least five different fields (original magnification, x200). Means ± SD were recorded for each condition, and an index was calculated based on the control involving random migration.
Matrigel invasion assay.
Cell invasion was quantified in vitro using matrigel-coated semipermeable, modified inserts with a pore size of 8-µm. Analysis of the invasion assay was performed as described in the chemotaxis assay incubated with CCL19 for 36 h. An invasion index was normalized to non-specific cell invasion (from media-pulsed wells).
Scrape wound-healing assay. Migration of PCI-37B cells was measured using an in vitro monolayer wound assay (20) . Cells grown in 24-well plates in DMEM to confluence were scraped with a pipette tip to create a cell-free area. Wounded monolayers were washed with serum-free media. The cells were pretreated with/without RhoA inhibitor C3 exoenzyme (50 ng/ml), Y-27632 ROCK inhibitor (10 M) and CCL19 (200 ng/ml) for 1 h. Wound closure was followed after 0 and 24 h. The wound-healing effect was calculated as the percentage of the remaining cell-free area compared to the initial wound area (arbitrarily set as 100%). Monolayer wound assays included serum-free DMEM controls. The wounds were observed by phase contrast microscopy (Nikon TE2000-S Eclipse) at x200 magnification and images captured were documented with photography. Each experiment was performed in triplicate, analyzing four or five scratches per well. The relative cell-free area was calculated based on the control group.
RhoA pull-down assay. RhoA-GTP was measured with recombinant purified glutathione-S-transferase rhotekin Rho-binding domain (GST-TRBD) bound to glutathione beads and purified as previously described (21) . SCCHN cells were stimulated with CCL19 in serum-free medium lysed with ice-cold RIPA buffer and cleared by centrifugation. SCCHN cell lysates were incubated for 1 h at 4˚C with GST or GST-TRBD coupled to glutathione-sepharose beads. Beads were then washed and boiled in SDS sample buffer and precipitates were analyzed with immunoblotting using an anti-RhoA antibody and then developed using chemiluminescence.
Western blotting. Cells were harvested in a lysis buffer (10 mM Tris-HCl, pH 7.6, 50 mM NaF, 1 mM Nav 3 O 4 , 1% Triton X-100 and 1X protease inhibitor of protein tyrosine phosphatases). Lysates were sonicated for 3 sec and centrifuged at 4˚C at 12,000 rpm for 30 min. The supernatant was collected for protein quantification using the Bio-Rad protein assay dye reagent. Protein (50 mg) was size-fractionated through a 10% SDS-PAGE gel and transferred onto nitrocellulose filters which were blocked (1% non-fat dry milk, 0.1% Triton X-100, 150 mM NaCl, 50 mM Tris, pH 7.5) and incubated with primary antibody (1:1,000 dilution). Nitrocellulose filters were incubated with horseradish peroxidase-conjugated secondary antibodies and bands were visualized with enhanced chemiluminescence and quantified by scanning densitometry using Imagej software.
Statistical analysis. Experiments were run in triplicate and repeated at least three times. Numerical data were expressed as means ± standard deviation (SD). Correlations were analyzed using the Spearman's and χ 2 tests. Statistical differences between two groups were evaluated using an unpaired Student's t-test. P<0.05 was considered to indicate a statistically significant result. Statistical analyses were performed with SPSS 13.0 software.
Results

CCR7 and RhoA are overexpressed and CCR7 and RhoA expression is significantly positively correlated in SCCHN.
Immunohistochemistry was utilized to examine CCR7 and RhoA expression in SCCHN tumor tissues, metastatic and normal lymph nodes and oral mucosal tissues. CCR7 and RhoA were evident in the cell membrane and cytoplasm, and were mainly expressed in the stromal surroundings of tumors and metastatic lymph node cells. Stained cells were few or absent in normal lymph nodes and oral mucosal tissues (Fig. 1) controlled by small GTPase Rho (16), we investigated whether CCR7 induces the activation of RhoA in an SCCHN cell line (PCI-37B). We measured activated RhoA (GTP-bound form) with Rho-binding domain (RBD) pull-down assays using the Rho effector protein, Rhotekin (23) . Limited active bound RhoA was observed in non-stimulated cells, and this was increased after CCL19 stimulation. Although total RhoA remained unchanged, activated RhoA increased significantly 10 min after CCL19 treatment compared with the controls (P<0.05), whereas CCR7mAb, a C3-exo-enzyme, partly inhibited the CCL19-induced activation of RhoA compared with the CCL19-stimulation group (P<0.05; Fig. 2 ).
RhoA/ROCK regulates CCR7-dependent migration and invasion. using chemotaxis and matrigel invasion assay we analyzed the role of RhoA in PCI-37B migration and invasiveness in response to CCL19. The presence of CCL19 in the lower chamber stimulated a >1.5-fold increase in chemotaxis and invasion of PCI-37B across the filter membrane while C3 and Y-27632 blocked this activity (P<0.05; Figs. 3 and 4) . In addition, we evaluated the migration ability of PCI-37B induced by CCR7 using a scrape wound-healing assay. The width of the wound, which was significantly reduced after 24 h in the presence of CCL19, and this was blocked by C3 and Y-27632 (P<0.05; Fig. 5 ). Data show that RhoA/ROCK has a role in the invasiveness of PCI-37B mediated by CCR7. 
+-+++ -Total +-+++  36  18  54  -10  11  21  Total  46  29  75 CCR7, chemokine receptor 7; SCCHN, squamous cell carcinoma of the head and neck. RhoA/ROCK mediates the activation of Pyk2 and cofilin in duced by CCL19. Western blotting indicated that CCL19-pretreated PCI-37B cells had an increased expression of p-Pyk2 (Fig. 6 ) and significantly decreased expression of p-cofilin (Fig. 7) , which was reversed by CCR7mAb, suggesting CCR7-induced activation of Pyk2 and cofilin. As expected, CCL19-dependent Pyk2 phosphorylation and cofilin dephosphorylation was abrogated in the presence of RhoA, ROCK and Pyk2 inhibitors, suggesting that RhoA/ROCK may mediate the activation of Pyk2 and cofilin induced by CCL19. The results showed that MLC protein was not changed after CCL19 stimulation, indicating that CCR7 has no effect on MLC (Fig. 8) .
Discussion
A critical problem in SCCHN therapy is metastasis, particularly to lymph nodes, lung, liver and bone. Metastasis is based on chemotaxis and the migratory ability of tumor cells. CCR7 induces chemotaxis and invasion of SCCHN cells via the activation of several signaling pathways (9) (10) (11) (24) (25) (26) . However, how migration is influenced by the signaling pathway remains poorly understood. RhoA is also involved in regulating the migration and invasion of diverse tumor types. RiolBlanco et al revealed that CCR7 activates the Rho/Pyk2/cofilin signaling pathway, which controls chemotaxis and the migratory speed of dendritic cells (14) . Other results also support a role for Rho/ROCK signaling in the regulation of CCR7-dependent chronic lymphocytic leukemia migration (15) . However, no reports are available to explain the role of RhoA in SCCHN. Our experiments indicate that RhoA and CCR7 are highly expressed in SCCHN and metastatic lymph-node cells. RhoA and CCR7 expression was significantly correlated with cervical lymph-node metastasis and SCCHN clinical stage. A Spearman's test indicated a significant positive correlation between expression of CCR7 and RhoA. Therefore, RhoA may be necessary for the development and metastasis of SCCHN, while CCR7 may regulate cell migration and survival via the RhoA pathway in SCCHN. RhoA is upregulated in various human tumor types. RhoA stimulates cell cycle progression and cytokinesis, as well as cell migration (27) through its activity as a molecular switch cycling between an inactive guanosine diphosphate (GDP)-bound and an active guanosine triphosphate (GTP)-bound form (28, 29) . A RhoA pull-down assay indicated that CCL19 (CCR7 ligand) was able to induce RhoA activation 1.5-folds more compared with controls in PCI-37B cell lines. The specific inhibitor of RhoA (C3 exoenzyme) decreased RhoA-GTP to one-third of baseline and CCR7mAb decreased RhoA-GTP significantly, however, the total RhoA did not change. The results show that RhoA may participate in the downstream pathway of CCR7 in SCCHN metastasis. Chemotaxis and Matrigel invasion, and scrape wound-healing assay data confirmed that CCL19-induced cell migration and invasion was >1.5-times greater than that of the controls and this was blocked with C3 exoenzyme. These data also confirm that RhoA may be an important downstream effector of the CCR7 pathway in SCCHN metastasis.
Rho GTPases participate in various signal transduction pathways via the activation of multiple downstream effector proteins. An important downstream effector is ROCK (27) . Studies indicate that ROCK is a downstream effector mediating Rho tumor growth potential. ROCKs phosphorylate and activate LIMKs, which in turn phosphorylate and inactivate cofilin, an actin-regulatory protein (27, 30) that regulates the migration and invasion of cancer cells (31) . ROCKs also regulate actomyosin contractility in cells by increasing the phosphorylation of MLC, which in turn stimulates myosin II to interact with and move along actin filaments (17) .
Tyrosine kinase Pyk2 is involved in signaling from chemokine receptors in different cells (14) . Our recent results suggest that CCR7 promotes tumor metastasis by sequential activation of Pyk2 and cofilin followed by rearrangement of F-actin in SCCHN cells (25) . However, whether RhoA participated in that pathway is unknown. Western blot results indicate that CCR7 induced the activation of Pyk2 and cofilin. Furthermore, CCL19-dependent Pyk2 phosphorylation and cofilin dephosphorylation was blocked by the RhoA and ROCK inhibitors, suggesting that RhoA/ROCK may mediate the activation of cofilin and Pyk2 induced by CCL19 in SCCHN cells. MLC protein was not changed following CCL19 stimulation, suggesting that CCR7 has no effect on MLC.
In conclusion, CCR7 promotes tumor migration and invasiveness via the RhoA/ROCK pathway in metastatic SCCHN. Direct inhibition of ROCK, a downstream molecule of Rho GTPase, using a pharmacological inhibitor (Y-27632) or a molecular approach (dominant-negative expression vector) can produce substantial therapeutic effects suggesting that direct targeting of the RhoA/ROCK pathway, alone or in combination with other targets, may be promising as a chemotherapeutic target (32) . Fasudil (Y-27632), a potent and selective ROCK inhibitor, is relatively safe and effective for treating cardiovascular disease including cerebral and coronary vasospasm, angina, hypertension and heart failure. No serious adverse side-effects have been reported thus far (33) . Future studies are needed to identify the effectiveness and safety of ROCK inhibitors, specifically for treatment of SCCHN. We found that ROCK inhibition may offer a novel therapeutic strategy for the total management of SCCHN as well as inhibiting metastases.
